Fiscal Year Ending March 2027 Second Quarter (Interim) Financial Summary [Japanese GAAP] (Consolidated)

Overview of Performance

This financial summary reports consolidated results for the second quarter of the fiscal year ending March 2027. Net sales were 142,254 million yen (YoY 9.0% increase) and operating income was 12,745 million yen (YoY 22.0% increase), reflecting steady performance. Ordinary income decreased to 10,093 million yen (YoY -15.7%) due to factors including derivative valuation losses, and interim net income attributable to owners of parent was 6,866 million yen (YoY -16.4%). By segment, revenue increased to 111,477 million yen domestically and 31,134 million yen internationally.

Outlook and Impact for Investors

Full-year earnings guidance is maintained, and the dividend policy continues with 40 yen per share at the end of the second quarter and a full-year plan of 85 yen for the fiscal year ending March 2027. The company aims to secure future supply stability and growth by expanding production capacity and strengthening collaborations both domestically and internationally. Notably, expansion of overseas operations and capacity increases through strategic partnerships such as with Tanabe Pharma Factory are key focus areas.